Scientific Reports (Oct 2024)

Sublingual microcirculatory assessment on admission independently predicts the outcome of old intensive care patients suffering from shock

  • Raphael Romano Bruno,
  • Mara Schemmelmann,
  • Johanna Hornemann,
  • Helene Mathilde Emilie Moecke,
  • Filiz Demirtas,
  • Lina Palici,
  • Radost Marinova,
  • Dominika Kanschik,
  • Stephan Binnebößel,
  • Armin Spomer,
  • Bertrand Guidet,
  • Susannah Leaver,
  • Hans Flaatten,
  • Wojciech Szczeklik,
  • Maciej Mikiewicz,
  • Dylan W. De Lange,
  • Stanislas Quenard,
  • Michael Beil,
  • Malte Kelm,
  • Christian Jung

DOI
https://doi.org/10.1038/s41598-024-77357-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Shock is a life-threatening condition. This study evaluated if sublingual microcirculatory perfusion on admission is associated with 30-day mortality in older intensive care unit (ICU) shock patients. This trial prospectively recruited ICU patients (≥ 80 years old) with arterial lactate above 2 mmol/L, requiring vasopressors despite adequate fluid resuscitation, regardless of shock cause. All patients received sequential sublingual measurements on ICU admission (± 4 h) and 24 (± 4) hours later. The primary endpoint was 30-day mortality. From September 4th, 2022, to May 30th, 2023, 271 patients were screened, and 44 included. Patients were categorized based on the median percentage of perfused small vessels (sPPV) into those with impaired and sustained microcirculation. 71% of videos were of good or acceptable quality without safety issues. Patients with impaired microcirculation had significantly shorter ICU and hospital stays (p = 0.015 and p = 0.019) and higher 30-day mortality (90.0% vs. 62.5%, p = 0.036). Cox regression confirmed the independent association of impaired microcirculation with 30-day mortality (adjusted hazard ratio 3.245 (95% CI 1.178 to 8.943, p = 0.023). Measuring sublingual microcirculation in critically ill older patients with shock on ICU admission is safe, feasible, and provides independent prognostic information about outcomes. Trial registration NCT04169204.

Keywords